Your browser doesn't support javascript.
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen, Yuxin; Chen, Lin; Yin, Shengxia; Tao, Yue; Zhu, Liguo; Tong, Xin; Mao, Minxin; Li, Ming; Wan, Yawen; Ni, Jun; Ji, Xiaoyun; Dong, Xianchi; Li, Jie; Huang, Rui; Shen, Ya; Shen, Han; Bao, Changjun; Wu, Chao.
  • Chen Y; Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Chen L; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
  • Yin S; Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
  • Tao Y; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
  • Zhu L; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Tong X; Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
  • Mao M; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People's Republic of China.
  • Li M; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
  • Wan Y; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Ni J; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Ji X; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Dong X; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Li J; Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, People's Republic of China.
  • Huang R; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
  • Shen Y; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People's Republic of China.
  • Shen H; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
  • Bao C; Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing, People's Republic of China.
  • Wu C; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
Emerg Microbes Infect ; 11(1): 1524-1536, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1860763
ABSTRACT
The waning humoral immunity and emerging contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants resulted in the necessity of the booster vaccination of coronavirus disease 2019 (COVID-19). The inactivated vaccine, CoronaVac, is the most widely supplied COVID-19 vaccine globally. Whether the CoronaVac booster elicited adaptive responses that cross-recognize SARS-CoV-2 variants of concern (VoCs) among 77 healthy subjects receiving the third dose of CoronaVac were explored. After the boost, remarkable elevated spike-specific IgG and IgA responses, as well as boosted neutralization activities, were observed, despite 3.0-fold and 5.9-fold reduced neutralization activities against Delta and Omicron strains compared to that of the ancestral strain. Furthermore, the booster dose induced potent B cells and memory B cells that cross-bound receptor-binding domain (RBD) proteins derived from VoCs, while Delta and Omicron RBD-specific memory B cell recognitions were reduced by 2.7-fold and 4.2-fold compared to that of ancestral strain, respectively. Consistently, spike-specific circulating follicular helper T cells (cTfh) significantly increased and remained stable after the boost, with a predominant expansion towards cTfh17 subpopulations. Moreover, SARS-CoV-2-specific CD4+ and CD8+ T cells peaked and sustained after the booster. Notably, CD4+ and CD8+ T cell recognition of VoC spike was largely preserved compared to the ancestral strain. Individuals without generating Delta or Omicron neutralization activities had comparable levels of CD4+ and CD8+ T cells responses as those with detectable neutralizing activities. Our study demonstrated that the CoronaVac booster induced broad and potent adaptive immune responses that could be effective in controlling SARS-CoV-2 Delta and Omicron variants.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article